FIG. 2.

Evaluation of AAV8.TBG.hLDLR in LA-DKO/hApoB-Tg mice. (A) Representative Western blot examining human LDLR (hLDLR) protein expression in liver lysates on day 35 after vector administration. (B) Plasma cholesterol, (C) non-HDL cholesterol, and (D) triglyceride levels were examined in LA-DKO/hApoB-Tg mice after treatment with AAV8.TBG.hLDLR (n=10 animals per dose group). Each point represents the mean±SD. ***p<0.001. (E) Evaluation of AAV8.TBG.hLDLR in LA-DKO and LA-DKO/hApoB-Tg mice. Presented is the average reduction in serum cholesterol as a function of vector dose (GC/kg).